​

Covalon Technologies Ltd.

TSXV:COV Stock Report

Market Cap: CA$75.1m

Covalon Technologies (COV) Stock Overview

Engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. More details

COV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Trading at 92.6% below our estimate of its fair value

Revenue is forecast to grow 9.14% per year

Became profitable this year

Risk Analysis

Does not have a meaningful market cap (CA$75M)


COV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Covalon Technologies Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Covalon Technologies
Historical stock prices
Current Share PriceCA$2.74
52 Week HighCA$4.30
52 Week LowCA$2.05
Beta0.090
1 Month Change17.60%
3 Month Change16.60%
1 Year Change31.73%
3 Year Change12.30%
5 Year Change136.21%
Change since IPO-8.67%

Recent News & Updates

Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S Ratio

Feb 26
Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S Ratio

Recent updates

Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S Ratio

Feb 26
Some Shareholders Feeling Restless Over Covalon Technologies Ltd.'s (CVE:COV) P/S Ratio

Subdued Growth No Barrier To Covalon Technologies Ltd. (CVE:COV) With Shares Advancing 29%

Nov 17
Subdued Growth No Barrier To Covalon Technologies Ltd. (CVE:COV) With Shares Advancing 29%

Covalon Technologies Ltd.'s (CVE:COV) 25% Share Price Surge Not Quite Adding Up

Aug 18
Covalon Technologies Ltd.'s (CVE:COV) 25% Share Price Surge Not Quite Adding Up

We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth

Aug 10
We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth

Optimistic Investors Push Covalon Technologies Ltd. (CVE:COV) Shares Up 83% But Growth Is Lacking

Jun 16
Optimistic Investors Push Covalon Technologies Ltd. (CVE:COV) Shares Up 83% But Growth Is Lacking

Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth Plans

May 01
Covalon Technologies (CVE:COV) Is In A Good Position To Deliver On Growth Plans

Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Feb 17
Covalon Technologies Ltd.'s (CVE:COV) Price Is Right But Growth Is Lacking After Shares Rocket 25%

Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share Price

Dec 22
Insufficient Growth At Covalon Technologies Ltd. (CVE:COV) Hampers Share Price

We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth

Sep 02
We Think Covalon Technologies (CVE:COV) Can Afford To Drive Business Growth

We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth Carefully

May 26
We Think Covalon Technologies (CVE:COV) Needs To Drive Business Growth Carefully

Is Covalon Technologies (CVE:COV) Using Too Much Debt?

Apr 29
Is Covalon Technologies (CVE:COV) Using Too Much Debt?

Covalon Technologies (CVE:COV) Is Making Moderate Use Of Debt

Dec 29
Covalon Technologies (CVE:COV) Is Making Moderate Use Of Debt

Shareholder Returns

COVCA BiotechsCA Market
7D4.2%-2.2%0.3%
1Y31.7%24.7%16.9%

Return vs Industry: COV exceeded the Canadian Biotechs industry which returned 23.8% over the past year.

Return vs Market: COV exceeded the Canadian Market which returned 17.9% over the past year.

Price Volatility

Is COV's price volatile compared to industry and market?
COV volatility
COV Average Weekly Movement6.1%
Biotechs Industry Average Movement9.4%
Market Average Movement8.8%
10% most volatile stocks in CA Market18.3%
10% least volatile stocks in CA Market3.1%

Stable Share Price: COV has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: COV's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004n/aBrent Ashtonwww.covalon.com

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone. It also offers medical coating platform, a process that utilizes photo-polymerization to create active grafting sites where new polymer chains are initiated and propagated from the surface of an existing medical device.

Covalon Technologies Ltd. Fundamentals Summary

How do Covalon Technologies's earnings and revenue compare to its market cap?
COV fundamental statistics
Market capCA$75.13m
Earnings (TTM)CA$3.70m
Revenue (TTM)CA$33.84m
20.3x
P/E Ratio
2.2x
P/S Ratio

Is COV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
COV income statement (TTM)
RevenueCA$33.84m
Cost of RevenueCA$13.94m
Gross ProfitCA$19.91m
Other ExpensesCA$16.21m
EarningsCA$3.70m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)0.13
Gross Margin58.82%
Net Profit Margin10.92%
Debt/Equity Ratio0%

How did COV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/13 08:09
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Covalon Technologies Ltd. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andre UddinResearch Capital Corporation